The company (“Baiyang Pharmaceutical” for short, stock code: 301015) was founded in 2005 and is China's leading health brand commercialization platform. Its business areas cover global brand operation, wholesale distribution and retail of high-quality medical and health products. Focusing on the development strategy of “commercial breakthrough, ecological innovation”, Baiyang Pharmaceutical is guided by optimizing the medical scenario. It is developing and upgrading from a health brand commercialization platform to an ecological BigPharma. Through the integration of scientific and technological innovation resources and incubation capabilities, it is building a platform for transforming scientific research achievements, and continuously cultivating healthcare products and services with independent intellectual property rights. The company's main business is to provide comprehensive commercial solutions for pharmaceutical product manufacturers, including providing brand operation, wholesale distribution and retail of pharmaceutical products, especially product marketing and promotion solutions for branded pharmaceutical manufacturers. Main products or business: Operates brands such as DiQiao series, Bite series, Halle series, Takeda series and Roche series, Cornice, Esnona, Newt Schuma, Atricure, Fuzhenghua, Zisheng; distributes pharmaceuticals, Chinese medicine tablets, medical devices, diagnostic reagents, medical consumables, etc.; sells pharmaceuticals, medical equipment, health food, cosmetics, etc. Corporate honors: Top 50 service enterprises in Shandong in 2021, the first batch of Chinese OTC brand clusters, 2021 Pharmaceutical Industry “13th Five-Year Plan” Enterprise Management Award - Outstanding Growing Enterprises, etc.